A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO)

Status Terminated

Clinical Trial Summary

Clinical Trial Description

This trial will be a phase 2, open-label, study to evaluate the safety, tolerability, and efficacy of VIR007 when administered topically for up to 60 days to adults between the ages of 18 to 65 years with a clinical diagnosis of external condylomata acuminata. Subjects will enter the Screening Period once the informed consent process has been completed. Subjects with a clinical diagnosis of external condylomata acuminata and who meet all inclusion and none of the exclusion criteria will be enrolled. Once subject eligibility is confirmed and the screening procedures completed, the subject will start the Treatment Period of the study. All enrolled subjects will receive VIR007 (cream containing 10% EISO) with the first dose applied topically during Visit 1 (Day 1). Subjects will be instructed on how to apply the study medication twice daily for up to 60 days or until the Investigator determines the lesions have cleared. Subjects will return to the clinic for study-related assessments on Study Days 7, 14, 28, 42 and a Final Study Visit on Day 60. 30 days following complete resolution, as determined by the study investigator, or, on Study Day 90, subjects will receive a follow-up telephone call and be queried regarding condition status since study completion. ;

Study Design

Related Conditions & MeSH terms

Condylomata Acuminata

Clinical Trial Details

NCT number	NCT03158974
Study type	Interventional
Source	ViroXis Corporation
Contact
Status	Terminated
Phase	Phase 2
Start date	August 1, 2017
Completion date	June 17, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04537156` - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Phase 3
Completed	`NCT00090285` - An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)	Phase 3
Completed	`NCT00973856` - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands	N/A
Completed	`NCT02015260` - A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts	Phase 2
Active, not recruiting	`NCT05056402` - An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old	Phase 3
Withdrawn	`NCT00365443` - Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)	Phase 2
Not yet recruiting	`NCT01483794` - Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile	N/A
Completed	`NCT03935204` - Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Phase 2
Completed	`NCT02405520` - Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine	Phase 1
Active, not recruiting	`NCT02710851` - Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine	Phase 2
Completed	`NCT04782895` - Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age	Phase 3
Completed	`NCT03546842` - Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)	Phase 3
Completed	`NCT03981822` - A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts	Phase 2
Recruiting	`NCT03158480` - Safety and Efficacy of Immune Therapy for Condyloma	N/A
Completed	`NCT01598779` - Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population	N/A
Not yet recruiting	`NCT06430190` - Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata	N/A
Completed	`NCT00449982` - Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts	Phase 3
Completed	`NCT03813940` - Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)	Phase 1
Not yet recruiting	`NCT06197802` - Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
Completed	`NCT01532102` - Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts	Phase 1/Phase 2

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms